Featured Research

from universities, journals, and other organizations

Herceptin plus taxol highly effective in low-risk breast cancer

Date:
December 11, 2013
Source:
Loyola University Health System
Summary:
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer Symposium.

"This is great news for patients and their physicians," said Kathy Albain, MD, of Loyola University Medical Center, who is one of the co-authors of the national multicenter study. "This study identifies a new treatment option for this population of patients that is highly effective and has minimal side effects." First author is Sara Tolaney, MD, of the Dana-Farber Cancer Institute.

About 1 in 4 breast patients have HER2+ breast cancer, meaning their cancer cells have a receptor protein on the surface known as HER2 (Human Epidermal growth factor Receptor 2).

Herceptin is part of the well-established standard-of-care for higher-risk HER2+ patients. But there currently is no single standard treatment patients with the for lower-risk HER2+ biology. In these patients, their tumors are small and the cancer has not spread to lymph nodes. Some of these patients currently are not receiving Herceptin, while others are being treated with Herceptin plus more toxic chemotherapy drugs.

The new study finds that an in-between treatment -- Herceptin plus a single chemotherapy drug Taxol -- is highly effective, with few adverse effects. Of the 406 patients studied, only 3.2 percent experienced severe neuropathy and only 0.5 percent experienced symptoms of congestive heart failure, which resolved after they discontinued Herceptin.


Story Source:

The above story is based on materials provided by Loyola University Health System. Note: Materials may be edited for content and length.


Cite This Page:

Loyola University Health System. "Herceptin plus taxol highly effective in low-risk breast cancer." ScienceDaily. ScienceDaily, 11 December 2013. <www.sciencedaily.com/releases/2013/12/131211131223.htm>.
Loyola University Health System. (2013, December 11). Herceptin plus taxol highly effective in low-risk breast cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/12/131211131223.htm
Loyola University Health System. "Herceptin plus taxol highly effective in low-risk breast cancer." ScienceDaily. www.sciencedaily.com/releases/2013/12/131211131223.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins